A randomized controlled trial to assess alendronate‐associated injury of the upper gastrointestinal tract
Authors:
Open Access
- 27 November 2000
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (11) , 1451-1457
Abstract
Background: Aminobisphosphonates are recommended for postmenopausal osteoporosis but have been associated with injury to the upper gastrointestinal tract.Aim: To conduct a randomized controlled trial, to assess the endoscopic damage caused by alendronate and its effect on gastric mucosal prostaglandin synthesis.Methods: Seventy‐six healthy volunteers age 40–60 years, with normal baseline endoscopy were randomly assigned to treatment with: (A) ASA 650 mg q.d.s.; (B) alendronate 10 mg o.d.; or (C) placebo o.d. for 14 days. Mucosal injury scores on day 14 of treatment were reported by a blinded endoscopist. Gastric biopsies were analysed for prostaglandin E2 (PGE2) concentration by radioimmunoassay.Results: Oesophageal injury did not differ among treatment groups. Gastric ulcers developed in five out of 26 subjects given ASA, two out of 25 given alendronate, and none of 25 given placebo. The mucosal damage scores for the alendronate group exceeded those for the placebo group in the gastric body but not at other sites. Injury scores for ASA exceeded those for placebo in the duodenum, antrum, body, and fundus. The mean change in log10[PGE2] (ng/mg protein) was − 0.07 for placebo, − 0.80 for ASA, and + 0.62 for alendronate (differences not significant).Conclusions: Alendronate is associated with injury and ulceration of the gastric mucosa. This effect was not associated with any significant change in gastric mucosal PGE2 levels.Keywords
This publication has 17 references indexed in Scilit:
- Upper Gastrointestinal Tract Safety Profile of AlendronateArchives of internal medicine (1960), 2000
- N‐bisphosphonates cause gastric epithelial injury independent of effects on the microcirculationAlimentary Pharmacology & Therapeutics, 1999
- Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronateCurrent Therapeutic Research, 1999
- Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelinesClinical Therapeutics, 1999
- Alendronate gastric ulcersAlimentary Pharmacology & Therapeutics, 1999
- So, where are all the celiacs?Gastroenterology, 1999
- Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with OsteoporosisPharmacoEconomics, 1998
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- The efect of indornethacin‐induced gastric rnucosal injury on 24‐h intragastric acidity and plasma gastrin concentration in healthy volunteersAlimentary Pharmacology & Therapeutics, 1995
- Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injuryDigestive Diseases and Sciences, 1990